Literature DB >> 27787272

What is the effect of pill burden on adherence to HIV antiretroviral therapy?

S Scott Sutton1, Divya Ahuja, Joseph Magagnoli.   

Abstract

Antiretroviral therapy (ART) is a combination treatment involving three or more antiretroviral agents for patients with HIV. ART has reduced HIV-related morbidity and mortality via single-tablet or multiple-tablet regimens. Single-tablet regimens, with their lower pill burdens, have demonstrated higher adherence rates, improved viral suppression, and reduced resource use compared with multiple-tablet regimens. In addition, select newer ARTs do not require the high levels of adherence for viral load suppression required by older ART formulations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27787272     DOI: 10.1097/01.JAA.0000502870.89587.b6

Source DB:  PubMed          Journal:  JAAPA        ISSN: 0893-7400


  4 in total

1.  Starting or Switching to an Integrase Inhibitor-Based Regimen Affects PTSD Symptoms in Women with HIV.

Authors:  Asante R Kamkwalala; Kunbo Wang; Yanxun Xu; Leah H Rubin; Jane O'Halloran; Dionna W Williams; Raha Dastgheyb; Kathryn C Fitzgerald; Amanda B Spence; Pauline M Maki; Deborah R Gustafson; Joel Milam; Anjali Sharma; Kathleen M Weber; Adaora A Adimora; Igho Ofotokun; Anandi N Sheth; Cecile D Lahiri; Margaret A Fischl; Deborah Konkle-Parker
Journal:  AIDS Behav       Date:  2021-01

2.  SESOTHO trial ("Switch Either near Suppression Or THOusand") - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa.

Authors:  Alain Amstutz; Bienvenu Lengo Nsakala; Fiona Vanobberghen; Josephine Muhairwe; Tracy Renée Glass; Beatrice Achieng; Mamorena Sepeka; Katleho Tlali; Lebohang Sao; Kyaw Thin; Thomas Klimkait; Manuel Battegay; Niklaus Daniel Labhardt
Journal:  BMC Infect Dis       Date:  2018-02-12       Impact factor: 3.090

3.  HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.

Authors:  Adriaan E Basson; Salome Charalambous; Christopher J Hoffmann; Lynn Morris
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

4.  Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma.

Authors:  Amedeo De Nicolò; Alessandra Manca; Alice Ianniello; Alice Palermiti; Andrea Calcagno; Micol Ferrara; Miriam Antonucci; Jessica Cusato; Valeria Avataneo; Elisa De Vivo; Stefano Bonora; Francesco Giuseppe De Rosa; Giovanni Di Perri; Antonio D'Avolio
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.